AbbVie Expands US AI Manufacturing As Risankizumab Trial Supports Valuation Gap
AbbVie (NYSE:ABBV) plans to invest US$380 million in two new US active pharmaceutical ingredient manufacturing facilities that will use artificial intelligence tools.
The company reported positive topline Phase 3 AFFIRM trial results for risankizumab in Crohn's disease patients.
AbbVie, known for its focus on immunology and oncology, is adding fresh momentum on both the operations and pipeline fronts. The new AI supported API plants signal a bigger push into US based production, while...
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.